Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives (GlobeNewswire) - Aug 14, 2023 - P1/2 | N=180 | NCT05194735 | Sponsor: Alaunos Therapeutics | "Interim Clinical Data from TCR-T Library Phase 1/2 Trial: Eight patients have been treated in the Company's TCR-T Library Phase 1/2 trial to date, six of which are evaluable as of today. The trial showed that the Company's T-cells were generally well-tolerated in all evaluable participants and achieved an 83% disease control rate in evaluable patients with metastatic, refractory solid tumors. Disease control is measured by objective responses and stable disease. Persistence of TCR-T cells in peripheral blood was detected in all evaluable patients at last follow-up....Alaunos has decided to wind down its TCR-T Library Phase 1/2 trial and prioritize the hunTR® platform to explore potential partnering opportunities."
P1/2 data • Trial status • Oncology • Solid Tumor
|